首页 > 最新文献

Clinica e Investigacion en Arteriosclerosis最新文献

英文 中文
Clonal hematopoiesis and atherosclerotic cardiovascular disease: A primer 克隆造血和动脉粥样硬化性心血管疾病:引物
IF 1.6 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2023-01-01 DOI: 10.1016/j.arteri.2021.09.006
María A. Zuriaga , José J. Fuster

Despite current standards of care, a considerable risk of atherosclerotic cardiovascular disease remains in both primary and secondary prevention. In this setting, clonal hematopoiesis driven by somatic mutations has recently emerged as a relatively common, potent and independent risk factor for atherosclerotic cardiovascular disease and other cardiovascular conditions. Experimental studies in mice suggest that mutations in TET2 and JAK2, which are among the most common in clonal hematopoiesis, increase inflammation and are causally connected to accelerated atherosclerosis development, which may explain the link between clonal hematopoiesis and increased cardiovascular risk. In this review, we provide an overview of our current understanding of this emerging cardiovascular risk factor.

尽管有目前的护理标准,但动脉粥样硬化性心血管疾病的相当大的风险仍然存在于一级和二级预防中。在这种情况下,由体细胞突变驱动的克隆性造血最近成为动脉粥样硬化性心血管疾病和其他心血管疾病的一个相对常见、有效和独立的风险因素。对小鼠的实验研究表明,在克隆性造血中最常见的TET2和JAK2突变会增加炎症,并与动脉粥样硬化的加速发展有因果关系,这可能解释了克隆性造血与心血管风险增加之间的联系。在这篇综述中,我们概述了我们目前对这一新兴心血管风险因素的理解。
{"title":"Clonal hematopoiesis and atherosclerotic cardiovascular disease: A primer","authors":"María A. Zuriaga ,&nbsp;José J. Fuster","doi":"10.1016/j.arteri.2021.09.006","DOIUrl":"10.1016/j.arteri.2021.09.006","url":null,"abstract":"<div><p>Despite current standards of care, a considerable risk of atherosclerotic cardiovascular disease remains in both primary and secondary prevention. In this setting, clonal hematopoiesis driven by somatic mutations has recently emerged as a relatively common, potent and independent risk factor for atherosclerotic cardiovascular disease and other cardiovascular conditions. Experimental studies in mice suggest that mutations in <em>TET2</em> and <em>JAK2</em>, which are among the most common in clonal hematopoiesis, increase inflammation and are causally connected to accelerated atherosclerosis development, which may explain the link between clonal hematopoiesis and increased cardiovascular risk. In this review, we provide an overview of our current understanding of this emerging cardiovascular risk factor.</p></div>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"35 1","pages":"Pages 35-41"},"PeriodicalIF":1.6,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10655612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Eating frequency has an inverse correlation with adiposity measures and non-invasive arterial stiffness parameters in healthy adult people 在健康成年人中,饮食频率与肥胖测量和非侵入性动脉僵硬参数呈负相关
IF 1.6 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2023-01-01 DOI: 10.1016/j.arteri.2022.06.004
Sajjad Arefinia , Lida Jarahi , Hamed Khedmatgozar , Saeed Eslami Hasan Abadi , Mohammad Reza Shadmand Foumani Moghadam , André Tchernof , Hosein Soleimaninia , Reza Rezvani

Background

Lifestyle modifications have been recommended as an essential treatment approach for cardiovascular diseases. Recent studies have shown that eating frequency (EF) correlates with hypertension and related risk of organ damage. This study aimed to examine critical clinical implications to evaluate the association of EF with arterial stiffness parameters as an early marker of atherosclerosis manifestations.

Methods

A cross-sectional descriptive study was performed on 658 participants of the PERSIAN Organizational Cohort study in Mashhad, aged 30–70 years. Arterial stiffness was assessed by measurement markers of arteriosclerosis, including arterial age, augmentation index (AIx), augmentation pressure (AP), carotid-femoral pulse wave velocity (Cf-PWV), and central blood pressure. Differences in anthropometric indices, blood indices, and arterial stiffness parameters were evaluated across EF groups.

Results

Our data demonstrate that EF was positively correlated with total daily energy intake, and favourable profiles of adiposity and blood lipids. Subjects with an increased EF, had significantly lower AIx, AP, Arterial Age and Central blood pressure (P for trend < 0.001) as compared to Lowest EF and not significant with PWV (P for trend, 0.19). Arterial stiffness was also significantly lower in those with increased EF compared with subjects with low EF. By Linear regression analysis, after adjustment for Confounding factors, except PWV, EF showed the associations with all of the non-invasive arterial stiffness parameters.

Conclusion

Increased EF is associated with a lower wave reflection and blood pressure in the central arteries.

背景生活方式的改变已被推荐为心血管疾病的一种基本治疗方法。最近的研究表明,进食频率(EF)与高血压和相关的器官损伤风险相关。本研究旨在探讨EF与动脉硬化参数的相关性的重要临床意义,该参数是动脉粥样硬化表现的早期标志。方法在马什哈德对658名年龄在30-70岁之间的PERSIAN组织队列研究参与者进行横断面描述性研究。通过测量动脉硬化标志物来评估动脉硬化,包括动脉年龄、增强指数(AIx)、增强压力(AP)、颈动脉-股动脉脉搏波速度(Cf-PWV)和中心血压。在EF组之间评估人体测量指数、血液指数和动脉硬度参数的差异。结果我们的数据表明,EF与每日总能量摄入呈正相关,与肥胖和血脂呈正相关。与最低EF相比,EF增加的受试者的AIx、AP、动脉年龄和中心血压显著降低(趋势<0.001的P),而PWV则不显著(趋势为0.19的P)。通过线性回归分析,在校正了Confounding因素后,除PWV外,EF与所有非侵入性动脉硬化参数均相关。结论EF升高与中心动脉波反射和血压降低有关。
{"title":"Eating frequency has an inverse correlation with adiposity measures and non-invasive arterial stiffness parameters in healthy adult people","authors":"Sajjad Arefinia ,&nbsp;Lida Jarahi ,&nbsp;Hamed Khedmatgozar ,&nbsp;Saeed Eslami Hasan Abadi ,&nbsp;Mohammad Reza Shadmand Foumani Moghadam ,&nbsp;André Tchernof ,&nbsp;Hosein Soleimaninia ,&nbsp;Reza Rezvani","doi":"10.1016/j.arteri.2022.06.004","DOIUrl":"10.1016/j.arteri.2022.06.004","url":null,"abstract":"<div><h3>Background</h3><p>Lifestyle modifications have been recommended as an essential treatment approach for cardiovascular diseases. Recent studies have shown that eating frequency (EF) correlates with hypertension and related risk of organ damage. This study aimed to examine critical clinical implications to evaluate the association of EF with arterial stiffness parameters as an early marker of atherosclerosis manifestations.</p></div><div><h3>Methods</h3><p>A cross-sectional descriptive study was performed on 658 participants of the PERSIAN Organizational Cohort study in Mashhad, aged 30–70 years. Arterial stiffness was assessed by measurement markers of arteriosclerosis, including arterial age, augmentation index (AIx), augmentation pressure (AP), carotid-femoral pulse wave velocity (Cf-PWV), and central blood pressure. Differences in anthropometric indices, blood indices, and arterial stiffness parameters were evaluated across EF groups.</p></div><div><h3>Results</h3><p>Our data demonstrate that EF was positively correlated with total daily energy intake, and favourable profiles of adiposity and blood lipids. Subjects with an increased EF, had significantly lower AIx, AP, Arterial Age and Central blood pressure (<em>P</em> for trend<!--> <!-->&lt;<!--> <!-->0.001) as compared to Lowest EF and not significant with PWV (<em>P</em> for trend, 0.19). Arterial stiffness was also significantly lower in those with increased EF compared with subjects with low EF. By Linear regression analysis, after adjustment for Confounding factors, except PWV, EF showed the associations with all of the non-invasive arterial stiffness parameters.</p></div><div><h3>Conclusion</h3><p>Increased EF is associated with a lower wave reflection and blood pressure in the central arteries.</p></div>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"35 1","pages":"Pages 21-31"},"PeriodicalIF":1.6,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10662930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Vascular smooth muscle cell aging: Insights from Hutchinson-Gilford progeria syndrome 血管平滑肌细胞老化:从Hutchinson-Gilford早衰综合征的见解
IF 1.6 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2023-01-01 DOI: 10.1016/j.arteri.2021.11.002
Magda R. Hamczyk , Rosa M. Nevado

Vascular smooth muscle cells (VSMCs) constitute the principal cellular component of the medial layer of arteries and are responsible for vessel contraction and relaxation in response to blood flow. Alterations in VSMCs can hinder vascular system function, leading to vascular stiffness, calcification and atherosclerosis, which in turn may result in life-threatening complications. Pathological changes in VSMCs typically correlate with chronological age; however, there are certain conditions and diseases, such as Hutchinson-Gilford progeria syndrome (HGPS), that can accelerate this process, resulting in premature vascular aging. HGPS is a rare genetic disorder characterized by severe VSMC loss, accelerated atherosclerosis and death from myocardial infarction or stroke during the adolescence. Because experiments with mouse models have demonstrated that alterations in VSMCs are responsible for early atherosclerosis in HGPS, studies on this disease can provide insights into the mechanisms of vascular aging and assess the relative contribution of VSMCs to this process.

血管平滑肌细胞(VSMCs)构成动脉中层的主要细胞成分,负责血管对血流的收缩和舒张。VSMCs的改变会阻碍血管系统功能,导致血管硬化、钙化和动脉粥样硬化,进而可能导致危及生命的并发症。VSMCs的病理变化通常与年龄相关;然而,某些情况和疾病,如Hutchinson-Gilford早衰综合征(HGPS),会加速这一过程,导致血管过早衰老。HGPS是一种罕见的遗传性疾病,其特征是青少年时期VSMC严重丧失、动脉粥样硬化加速以及心肌梗死或中风死亡。因为用小鼠模型进行的实验已经证明,VSMCs的改变是HGPS早期动脉粥样硬化的原因,所以对这种疾病的研究可以深入了解血管老化的机制,并评估VSMCs对这一过程的相对贡献。
{"title":"Vascular smooth muscle cell aging: Insights from Hutchinson-Gilford progeria syndrome","authors":"Magda R. Hamczyk ,&nbsp;Rosa M. Nevado","doi":"10.1016/j.arteri.2021.11.002","DOIUrl":"10.1016/j.arteri.2021.11.002","url":null,"abstract":"<div><p>Vascular smooth muscle cells (VSMCs) constitute the principal cellular component of the medial layer of arteries and are responsible for vessel contraction and relaxation in response to blood flow. Alterations in VSMCs can hinder vascular system function, leading to vascular stiffness, calcification and atherosclerosis, which in turn may result in life-threatening complications. Pathological changes in VSMCs typically correlate with chronological age; however, there are certain conditions and diseases, such as Hutchinson-Gilford progeria syndrome (HGPS), that can accelerate this process, resulting in premature vascular aging. HGPS is a rare genetic disorder characterized by severe VSMC loss, accelerated atherosclerosis and death from myocardial infarction or stroke during the adolescence. Because experiments with mouse models have demonstrated that alterations in VSMCs are responsible for early atherosclerosis in HGPS, studies on this disease can provide insights into the mechanisms of vascular aging and assess the relative contribution of VSMCs to this process.</p></div>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"35 1","pages":"Pages 42-51"},"PeriodicalIF":1.6,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10669642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Valoración del estilo de vida saludable adquirido en adultos españoles de 22 a 72 años de edad 22至72岁西班牙成年人获得的健康生活方式评估
IF 1.6 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2023-01-01 DOI: 10.1016/j.arteri.2022.06.002
Pedro Luis Rodríguez García , Juan José Pérez Soto , Eliseo García Cantó , Marcos Meseguer Zafra , Raúl Salmerón Ríos , Pedro Juan Tárraga López

Objective

The objective of this paper has focused on assessing the level of health-related lifestyle acquired in Spanish adults in the Spanish cities of Albacete and Murcia, and analyzing the existing differences according to sex and age.

Material and methods

On a sample of 788 subjects aged between 22 and 72, the Health-related Lifestyle Assessment Scale was applied, consisting of 52 items and structured in 7 dimensions that explained a total variance of 66.87% and a Cronbach's alpha of 0.894.

Results

A percentage of 12 of the adults surveyed have a healthy lifestyle, 53% show a trend to health and 35% poor or unhealthy. Pearson's χ2 tests show a positive and significant association of women with health and a trend of significant improvement in lifestyle with age. The inferential data (t-Student tests and one-factor ANOVA) confirm these differences according to gender and age.

Conclusions

It is necessary to promote preventive programs to improve health in the habits of the population, especially in the 35% that show a poor or unhealthy level of lifestyle.

目的本文的目的是评估西班牙城市阿尔巴塞特和穆尔西亚的西班牙成年人获得的与健康相关的生活方式水平,并分析根据性别和年龄存在的差异。材料和方法在788名年龄在22岁至72岁之间的受试者中,应用了健康相关生活方式评估量表,该量表由52个项目组成,分为7个维度,解释了66.87%的总方差和0.894的克朗巴赫α。皮尔逊χ2检验显示,女性与健康呈正相关,并且随着年龄的增长,生活方式有显著改善的趋势。推断数据(t-学生检验和单因素方差分析)证实了性别和年龄的差异。结论有必要推广预防计划,以改善人群的健康习惯,尤其是35%的人群表现出较差或不健康的生活方式。
{"title":"Valoración del estilo de vida saludable adquirido en adultos españoles de 22 a 72 años de edad","authors":"Pedro Luis Rodríguez García ,&nbsp;Juan José Pérez Soto ,&nbsp;Eliseo García Cantó ,&nbsp;Marcos Meseguer Zafra ,&nbsp;Raúl Salmerón Ríos ,&nbsp;Pedro Juan Tárraga López","doi":"10.1016/j.arteri.2022.06.002","DOIUrl":"https://doi.org/10.1016/j.arteri.2022.06.002","url":null,"abstract":"<div><h3>Objective</h3><p>The objective of this paper has focused on assessing the level of health-related lifestyle acquired in Spanish adults in the Spanish cities of Albacete and Murcia, and analyzing the existing differences according to sex and age.</p></div><div><h3>Material and methods</h3><p>On a sample of 788 subjects aged between 22 and 72, the Health-related Lifestyle Assessment Scale was applied, consisting of 52 items and structured in 7 dimensions that explained a total variance of 66.87% and a Cronbach's alpha of 0.894.</p></div><div><h3>Results</h3><p>A percentage of 12 of the adults surveyed have a healthy lifestyle, 53% show a trend to health and 35% poor or unhealthy. Pearson's χ<sup>2</sup> tests show a positive and significant association of women with health and a trend of significant improvement in lifestyle with age. The inferential data (t-Student tests and one-factor ANOVA) confirm these differences according to gender and age.</p></div><div><h3>Conclusions</h3><p>It is necessary to promote preventive programs to improve health in the habits of the population, especially in the 35% that show a poor or unhealthy level of lifestyle.</p></div>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"35 1","pages":"Pages 12-20"},"PeriodicalIF":1.6,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49827867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Síndrome de quilomicronemia familiar: primer caso reportado en Ecuador 家族性公里micronemia综合征:厄瓜多尔报告的第一例病例
IF 1.6 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2022-11-01 DOI: 10.1016/j.arteri.2022.08.002
Karla Johana Garay García , Ricardo Javier Chong Menendez , Juan Patricio Nogueira , Jefferson Santiago Piedra Andrade

Familial chylomicronemia syndrome (FCS) is a genetic entity with autosomal recessive inheritance. Mutations in genes (such as APOC2, APOAV, LMF-1, GPIHBP-1) that code for proteins that regulate the maturation, transport, or polymerization of lipoprotein lipase-1 are the most common causes, but not the only ones. The objective of this study was to report the first documented case in Ecuador.

Clinical case

A 38-year-old man presented with chronic hepatosplenomegaly, thrombocytopenia, pancreatic atrophy, and severe hypertriglyceridemia refractory to treatment. A molecular analysis was performed by next generation sequencing that determined a deficiency of Lipoprotein Lipase OMIM #238600 in homozygosis. Genetic confirmation is necessary in order to establish the etiology of HTGS for an adequate management of this pathology.

家族性乳糜微粒血症综合征(FCS)是一种常染色体隐性遗传。基因突变(如APOC2、APOAV、LMF-1、GPIHBP-1)编码调节脂蛋白脂酶-1成熟、转运或聚合的蛋白质是最常见的原因,但不是唯一的原因。本研究的目的是报告厄瓜多尔第一例有记录的病例。临床病例:一名38岁男性,以慢性肝脾肿大、血小板减少、胰腺萎缩和严重高甘油三酯血症难治性表现。通过下一代测序进行分子分析,确定纯合子中脂蛋白脂肪酶OMIM #238600缺乏。遗传确认是必要的,以便建立HTGS的病因,以适当地管理这种病理。
{"title":"Síndrome de quilomicronemia familiar: primer caso reportado en Ecuador","authors":"Karla Johana Garay García ,&nbsp;Ricardo Javier Chong Menendez ,&nbsp;Juan Patricio Nogueira ,&nbsp;Jefferson Santiago Piedra Andrade","doi":"10.1016/j.arteri.2022.08.002","DOIUrl":"10.1016/j.arteri.2022.08.002","url":null,"abstract":"<div><p>Familial chylomicronemia syndrome (FCS) is a genetic entity with autosomal recessive inheritance. Mutations in genes (such as APOC2, APOAV, LMF-1, GPIHBP-1) that code for proteins that regulate the maturation, transport, or polymerization of lipoprotein lipase-1 are the most common causes, but not the only ones. The objective of this study was to report the first documented case in Ecuador.</p></div><div><h3>Clinical case</h3><p>A 38-year-old man presented with chronic hepatosplenomegaly, thrombocytopenia, pancreatic atrophy, and severe hypertriglyceridemia refractory to treatment. A molecular analysis was performed by next generation sequencing that determined a deficiency of Lipoprotein Lipase OMIM #238600 in homozygosis. Genetic confirmation is necessary in order to establish the etiology of HTGS for an adequate management of this pathology.</p></div>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"34 6","pages":"Pages 326-329"},"PeriodicalIF":1.6,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40387860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Estrategias de tratamiento de las dislipemias en prevención primaria y secundaria. Registro de la Sociedad Española de Arteriosclerosis 血脂异常在一级和二级预防中的治疗策略。西班牙动脉硬化学会注册
IF 1.6 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2022-11-01 DOI: 10.1016/j.arteri.2022.03.007
Victoria Marco-Benedí , Ana M. Bea , Rosa M. Sánchez Hernández , Núria Plana , Pedro Valdivielso , Fernando Civeira

Introduction

Clinical studies show that patients with high cardiovascular risk are still far from reaching the therapeutic objectives, especially of the levels of LDL cholesterol. If the management of these patients in specialized units differs from other scenarios is known.

Patients and methods

61 certified Lipid Units were selected in the Registry of Dyslipemias of the Spanish Arteriosclerosis Society for the collection of study data.

The study included 3958 subjects >18 years of age who met the criteria for hypercholesterolemia (LDL cholesterol ≥160 mg/dL or non-HDL cholesterol ≥190 mg/dL) without familial hypercholesterolemia. A total 1,665 subjects were studied with a mean follow-up time of 4.2 years.

Results and conclusions

A total of 42 subjects had a cardiovascular event since their inclusion in the Registry, which represents 0.6%. There were no differences in the treatment used at follow-up, but 50% of the patients did not reach the therapeutic goals at the visit end of follow-up. An increase in the potency of the lipid-lowering treatment was observed, including PCSK9 inhibitors use in 16.7% of subjects with recurrences.

临床研究表明,心血管高危患者仍远未达到治疗目标,特别是低密度脂蛋白胆固醇水平。如果这些患者在专科病房的管理不同于其他情况是已知的。在西班牙动脉硬化学会的血脂异常登记处选择了61个经认证的脂质单位来收集研究数据。该研究包括3958名18岁符合高胆固醇血症标准(低密度脂蛋白胆固醇≥160 mg/dL或非高密度脂蛋白胆固醇≥190 mg/dL)且无家族性高胆固醇血症的受试者。共有1665名受试者被研究,平均随访时间为4.2年。结果和结论自纳入登记以来,共有42名受试者发生心血管事件,占0.6%。随访时所采用的治疗方法无差异,但有50%的患者在随访结束时未达到治疗目标。观察到降脂治疗的效力增加,包括16.7%的复发患者使用PCSK9抑制剂。
{"title":"Estrategias de tratamiento de las dislipemias en prevención primaria y secundaria. Registro de la Sociedad Española de Arteriosclerosis","authors":"Victoria Marco-Benedí ,&nbsp;Ana M. Bea ,&nbsp;Rosa M. Sánchez Hernández ,&nbsp;Núria Plana ,&nbsp;Pedro Valdivielso ,&nbsp;Fernando Civeira","doi":"10.1016/j.arteri.2022.03.007","DOIUrl":"10.1016/j.arteri.2022.03.007","url":null,"abstract":"<div><h3>Introduction</h3><p>Clinical studies show that patients with high cardiovascular risk are still far from reaching the therapeutic objectives, especially of the levels of LDL cholesterol. If the management of these patients in specialized units differs from other scenarios is known.</p></div><div><h3>Patients and methods</h3><p>61 certified Lipid Units were selected in the Registry of Dyslipemias of the Spanish Arteriosclerosis Society for the collection of study data.</p><p>The study included 3958 subjects &gt;18 years of age who met the criteria for hypercholesterolemia (LDL cholesterol ≥160 mg/dL or non-HDL cholesterol ≥190 mg/dL) without familial hypercholesterolemia. A total 1,665 subjects were studied with a mean follow-up time of 4.2 years.</p></div><div><h3>Results and conclusions</h3><p>A total of 42 subjects had a cardiovascular event since their inclusion in the Registry, which represents 0.6%. There were no differences in the treatment used at follow-up, but 50% of the patients did not reach the therapeutic goals at the visit end of follow-up. An increase in the potency of the lipid-lowering treatment was observed, including PCSK9 inhibitors use in 16.7% of subjects with recurrences.</p></div>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"34 6","pages":"Pages 303-310"},"PeriodicalIF":1.6,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54195074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Actualización sobre las nuevas formas de consumo de tabaco 关于新形式烟草消费的最新情况
IF 1.6 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2022-11-01 DOI: 10.1016/j.arteri.2022.03.004
Jorge Francisco Gómez Cerezo , José Enrique López Paz , Jacinto Fernández Pardo

Smoking remains the leading cause of morbidity and mortality worldwide. Because of its clear influence on cardiovascular and respiratory diseases, it is an important factor in internal medicine consultations. Although the rate of smoking cessation has been increasing in recent years, there is a percentage of patients who continue to smoke because they are unable or unwilling to quit, despite having tried existing pharmacological and non-pharmacological therapies. For this group of patients there are strategies based on interventions aimed at reducing the negative effects of smoking without the need for complete cessation. In this review it is shown that due to the absence of combustion of organic matter in conventional cigarettes, snus, e-cigarettes and heated tobacco products generate significantly lower levels of toxic substances.

吸烟仍然是全世界发病率和死亡率的主要原因。由于其对心血管和呼吸系统疾病的影响明显,是内科会诊的重要因素。尽管近年来戒烟率一直在上升,但仍有一定比例的患者继续吸烟,因为他们无法或不愿戒烟,尽管已经尝试了现有的药物和非药物治疗。对于这组患者,有一些基于干预措施的策略,旨在减少吸烟的负面影响,而不需要完全戒烟。这篇综述表明,由于传统香烟中没有有机物的燃烧,鼻烟、电子烟和加热烟草产品产生的有毒物质水平明显较低。
{"title":"Actualización sobre las nuevas formas de consumo de tabaco","authors":"Jorge Francisco Gómez Cerezo ,&nbsp;José Enrique López Paz ,&nbsp;Jacinto Fernández Pardo","doi":"10.1016/j.arteri.2022.03.004","DOIUrl":"10.1016/j.arteri.2022.03.004","url":null,"abstract":"<div><p>Smoking remains the leading cause of morbidity and mortality worldwide. Because of its clear influence on cardiovascular and respiratory diseases, it is an important factor in internal medicine consultations. Although the rate of smoking cessation has been increasing in recent years, there is a percentage of patients who continue to smoke because they are unable or unwilling to quit, despite having tried existing pharmacological and non-pharmacological therapies. For this group of patients there are strategies based on interventions aimed at reducing the negative effects of smoking without the need for complete cessation. In this review it is shown that due to the absence of combustion of organic matter in conventional cigarettes, snus, e-cigarettes and heated tobacco products generate significantly lower levels of toxic substances.</p></div>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"34 6","pages":"Pages 330-338"},"PeriodicalIF":1.6,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0214916822000377/pdfft?md5=02d6adb35580061a733a0d4895094a21&pid=1-s2.0-S0214916822000377-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54194768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efecto de la administración de diferentes formas de vitamina D en la presión arterial y rigidez aórticas, y su implicación en la reducción de la albuminuria en la enfermedad renal crónica 不同形式的维生素D对血压和主动脉僵硬的影响,以及它们在减少慢性肾脏疾病白蛋白尿中的作用
IF 1.6 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2022-11-01 DOI: 10.1016/j.arteri.2022.05.002
Almudena Martin-Romero , Jary Perelló-Martínez , Juan Carlos Hidalgo-Santiago , Alfredo Michan-Doña , Juan Bosco López Sáez , Pablo Gómez-Fernández
<div><h3>Background and objectives</h3><p>Vitamin D(vitD) participates in phospho-calcium metabolism and exerts multiple pleiotropic effects. There is tissue 1-α (OH)ase that converts 25-OH cholecalciferol (25 (OH) D) in calcitriol that exerts autocrine and paracrine effects. 25 (OH)D deficiency could limit these tissue effects of vitD. The administration of nutritional vitD and the activator of the vitD receptor, paricalcitol, may promote beneficial effects on vascular and renal function. The objective of this work was to study in subjects with chronic kidney disease (CKD) the effect that the administration of different forms of vitD has on arterial function and albuminuria, and the possible relationship between the modifications of these variables.</p></div><div><h3>Patients and methods</h3><p>We studied in 97 patients with CKD stages 3-4 the effect of the administration of cholecalciferol (group 2; n: 35) and paricalcitol (n: 31; group 3) on parameters derived from brachial blood pressure, aortic blood pressure and on aortic stiffness studied using carotid-femoral pulse velocity (Vp<sub>c-f</sub>), and on albuminuria. A group of patients with stages 3-4 CKD who did not receive vitD therapy served as a control group (n: 31; group 1). All parameters were studied at baseline and after the follow-up period which was 7 ± 2 months.</p></div><div><h3>Results</h3><p>In the baseline phase, no differences were observed between the groups in brachial systolic blood pressure (bSBP), central systolic blood pressure (SBP), brachial pulse pressure (bPP), and central pulse pressure (pCP) or in aortic stiffness that was increased in all groups with a baseline Vp<sub>c-f</sub> value of 10.5 (9.2-12.1) m/sec. The baseline albuminuria value in the grouped patients was 229 (43-876) mg / g (median (interquartile range)), with no differences between the groups.</p><p>Serum calcium and phosphorus increased significantly in those treated with cholecal-ciferol (native vitD) and paricalcitol (active vitD). Parathormone (PTH) values decreased in those treated with paricalcitol.bPP and cPP decreased in all groups treated with native and active vitD. No significant changes in bPP and cPP were observed in the control group.</p><p>Vp<sub>c-f</sub> did not change significantly in any of the groups, although the variation was quantitatively greater in group 3 (11.2±2 vs. 10.7±1.6 <em>(P=</em>.06)). No differences were observed in the changes in Vp<sub>c-f</sub> between the groups when adjusted to the baseline values of estimated glomerular filtration rate (eGFR), albuminuria, PTH, vitD, brachial and central blood pressure parameters, and their changes with treatment.Those who received treatment with native and active vitD presented a significant decrease in albuminuria of 17% (group 2) and 21% (group 3) compared to a 16% increase in the untreated group (group 1) <em>(P=</em>.01). A decrease in albuminuria ≥30% was observed more frequently in the groups treated with some form o
背景与目的维生素D(vitD)参与磷钙代谢,发挥多种多效作用。骨化三醇中有组织1-α (OH)酶转化25-OH胆骨化醇(25 (OH) D),发挥自分泌和旁分泌作用。缺乏25 (OH)D可以限制维生素D的这些组织作用。营养维生素d和维生素d受体的激活剂,特别是糖醇,可以促进血管和肾脏功能的有益作用。本研究的目的是研究慢性肾脏疾病(CKD)患者服用不同形式的维生素d对动脉功能和蛋白尿的影响,以及这些变量的改变之间可能的关系。患者和方法我们研究了97例CKD 3-4期患者给予胆钙化醇的效果(2组;N: 35)和paricalcitol (N: 31;第3组)肱血压、主动脉血压、颈-股动脉脉速(vc -f)研究的主动脉硬度参数和蛋白尿。一组未接受vitD治疗的3-4期CKD患者作为对照组(n: 31;1组)。在基线及随访(7±2个月)后进行各项指标的研究。结果基线期各组间肱收缩压(bSBP)、中心收缩压(SBP)、肱脉压(bPP)、中心脉压(pCP)均无差异,各组间主动脉硬度均升高,基线Vpc-f值为10.5 (9.2-12.1)m/sec。分组患者的基线蛋白尿值为229 (43-876)mg / g(中位数(四分位数范围)),组间无差异。血清钙和磷在使用胆-枸橼醇(天然维生素d)和部分枸橼醇(活性维生素d)治疗组显著升高。paricalcitol治疗组甲状旁腺激素(PTH)值降低。所有天然和活性维生素d治疗组的bPP和cPP均下降。对照组bPP、cPP无明显变化。Vpc-f在任何组中都没有显著变化,尽管在数量上变化在第3组更大(11.2±2比10.7±1.6 (P=.06))。当调整到肾小球滤过率(eGFR)、蛋白尿、甲状旁腺素(PTH)、vitD、肱和中枢血压参数的基线值时,两组间Vpc-f的变化及其随治疗的变化无差异。与未治疗组(1组)增加16%相比,接受天然和活性维生素d治疗的患者蛋白尿显著减少17%(2组)和21%(3组)(P= 0.01)。在接受某种形式维生素d治疗的组中,蛋白尿下降≥30%的情况更为常见(组2:23%;第3组:45%)高于对照组(13%)(P=.03)。当引入磷钙代谢的生化参数基线值、动脉功能(PPb、PPc、Vpc-f)或其修改值作为协变量时,任何形式的vitD治疗组观察到的蛋白尿减少都没有变化。Vpc-f变化与蛋白尿无显著相关性。在逻辑回归中,动脉功能参数的改变也不能解释蛋白尿减少≥30%的原因。结论在3-4期CKD患者中,接受RAS受体阻滞剂治疗并伴有残余蛋白尿,给予或特定的糖醇可降低肱动脉脉压和主动脉脉压以及蛋白尿。蛋白尿的减少似乎不是由中央血流动力学或主动脉僵硬的改变介导的,至少不是决定性的。
{"title":"Efecto de la administración de diferentes formas de vitamina D en la presión arterial y rigidez aórticas, y su implicación en la reducción de la albuminuria en la enfermedad renal crónica","authors":"Almudena Martin-Romero ,&nbsp;Jary Perelló-Martínez ,&nbsp;Juan Carlos Hidalgo-Santiago ,&nbsp;Alfredo Michan-Doña ,&nbsp;Juan Bosco López Sáez ,&nbsp;Pablo Gómez-Fernández","doi":"10.1016/j.arteri.2022.05.002","DOIUrl":"10.1016/j.arteri.2022.05.002","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background and objectives&lt;/h3&gt;&lt;p&gt;Vitamin D(vitD) participates in phospho-calcium metabolism and exerts multiple pleiotropic effects. There is tissue 1-α (OH)ase that converts 25-OH cholecalciferol (25 (OH) D) in calcitriol that exerts autocrine and paracrine effects. 25 (OH)D deficiency could limit these tissue effects of vitD. The administration of nutritional vitD and the activator of the vitD receptor, paricalcitol, may promote beneficial effects on vascular and renal function. The objective of this work was to study in subjects with chronic kidney disease (CKD) the effect that the administration of different forms of vitD has on arterial function and albuminuria, and the possible relationship between the modifications of these variables.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Patients and methods&lt;/h3&gt;&lt;p&gt;We studied in 97 patients with CKD stages 3-4 the effect of the administration of cholecalciferol (group 2; n: 35) and paricalcitol (n: 31; group 3) on parameters derived from brachial blood pressure, aortic blood pressure and on aortic stiffness studied using carotid-femoral pulse velocity (Vp&lt;sub&gt;c-f&lt;/sub&gt;), and on albuminuria. A group of patients with stages 3-4 CKD who did not receive vitD therapy served as a control group (n: 31; group 1). All parameters were studied at baseline and after the follow-up period which was 7 ± 2 months.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;p&gt;In the baseline phase, no differences were observed between the groups in brachial systolic blood pressure (bSBP), central systolic blood pressure (SBP), brachial pulse pressure (bPP), and central pulse pressure (pCP) or in aortic stiffness that was increased in all groups with a baseline Vp&lt;sub&gt;c-f&lt;/sub&gt; value of 10.5 (9.2-12.1) m/sec. The baseline albuminuria value in the grouped patients was 229 (43-876) mg / g (median (interquartile range)), with no differences between the groups.&lt;/p&gt;&lt;p&gt;Serum calcium and phosphorus increased significantly in those treated with cholecal-ciferol (native vitD) and paricalcitol (active vitD). Parathormone (PTH) values decreased in those treated with paricalcitol.bPP and cPP decreased in all groups treated with native and active vitD. No significant changes in bPP and cPP were observed in the control group.&lt;/p&gt;&lt;p&gt;Vp&lt;sub&gt;c-f&lt;/sub&gt; did not change significantly in any of the groups, although the variation was quantitatively greater in group 3 (11.2±2 vs. 10.7±1.6 &lt;em&gt;(P=&lt;/em&gt;.06)). No differences were observed in the changes in Vp&lt;sub&gt;c-f&lt;/sub&gt; between the groups when adjusted to the baseline values of estimated glomerular filtration rate (eGFR), albuminuria, PTH, vitD, brachial and central blood pressure parameters, and their changes with treatment.Those who received treatment with native and active vitD presented a significant decrease in albuminuria of 17% (group 2) and 21% (group 3) compared to a 16% increase in the untreated group (group 1) &lt;em&gt;(P=&lt;/em&gt;.01). A decrease in albuminuria ≥30% was observed more frequently in the groups treated with some form o","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"34 6","pages":"Pages 311-321"},"PeriodicalIF":1.6,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40493716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Tasas de prevalencia de sobrepeso y obesidad y sus asociaciones con factores cardiometabólicos y renales. Estudio SIMETAP-OB 超重和肥胖的患病率及其与心脏代谢和肾脏因素的关系。研究SIMETAP-OB
IF 1.6 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2022-11-01 DOI: 10.1016/j.arteri.2022.03.006
Antonio Ruiz-García , Ezequiel Arranz-Martínez , Luis Enrique Morales-Cobos , Juan Carlos García-Álvarez , Nerea Iturmendi-Martínez , Montserrat Rivera-Teijido , en representación del Grupo de Investigación del Estudio SIMETAP

Introduction

Excess weight is a major health problem. Aims of this study were to determine the prevalence rates of overweight and obesity, and to compare their associations with cardiometabolic and renal risk factors between obese and non-obese populations, and between overweight and non-overweight populations.

Methods

Cross-sectional observational study conducted in Primary Care. Population-based random sample: 6,588 study subjects between 18 and 102 years of age (response rate: 66%). Crude and sex- and age-adjusted prevalence rates of overweight and obesity were calculated, and their associations with cardiometabolic and renal variables were assessed by bivariate and multivariate analysis.

Results

The age- and sex-adjusted prevalence rates of overweight and obesity were 36.0% (42.1% in men; 33.1% in women) and 25.0% (26.2% in men; 24.5% in women), respectively. These prevalences increased with age, and were higher in men than in women. Fifty-two percent (95%CI: 50.0-53.9) of the overweight population and 62.3% (95%CI: 60.1-64.5) of the obese population had a high or very high cardiovascular risk. Abdominal obesity, physical inactivity, prediabetes, hypertension, hypertriglyceridemia, and low HDL-C were independently associated with both entities. Furthermore, diabetes was independently associated with overweight and hypercholesterolemia with obesity.

Conclusions

The prevalence of overweight and obesity was 61.0% (68.4% in men and 59.0% in women). More than half of the overweight population and nearly two-thirds of the obese population had a high cardiovascular risk. Hyperglycemia, physical inactivity, hypertension, hypercholesterolemia, low HDL-C, and hypertriglyceridemia were independently associated with overweight and obesity.

超重是一个主要的健康问题。本研究的目的是确定超重和肥胖的患病率,并比较肥胖和非肥胖人群、超重和非超重人群与心脏代谢和肾脏危险因素的关系。方法在初级保健部门进行横断面观察研究。基于人群的随机样本:6588名年龄在18至102岁之间的研究对象(应答率:66%)。计算超重和肥胖的粗患病率以及性别和年龄调整后的患病率,并通过双变量和多变量分析评估其与心脏代谢和肾脏变量的关联。结果经年龄和性别调整后的超重和肥胖患病率为36.0%(男性42.1%;女性33.1%)和25.0%(男性26.2%;女性为24.5%)。这些患病率随着年龄的增长而增加,男性高于女性。52% (95%CI: 50.0-53.9)的超重人群和62.3% (95%CI: 60.1-64.5)的肥胖人群有较高或非常高的心血管风险。腹部肥胖、缺乏运动、前驱糖尿病、高血压、高甘油三酯血症和低HDL-C与这两种实体独立相关。此外,糖尿病与超重和高胆固醇血症与肥胖独立相关。结论超重和肥胖患病率为61.0%,其中男性为68.4%,女性为59.0%。超过一半的超重人群和近三分之二的肥胖人群患心血管疾病的风险很高。高血糖、缺乏运动、高血压、高胆固醇血症、低HDL-C和高甘油三酯血症与超重和肥胖独立相关。
{"title":"Tasas de prevalencia de sobrepeso y obesidad y sus asociaciones con factores cardiometabólicos y renales. Estudio SIMETAP-OB","authors":"Antonio Ruiz-García ,&nbsp;Ezequiel Arranz-Martínez ,&nbsp;Luis Enrique Morales-Cobos ,&nbsp;Juan Carlos García-Álvarez ,&nbsp;Nerea Iturmendi-Martínez ,&nbsp;Montserrat Rivera-Teijido ,&nbsp;en representación del Grupo de Investigación del Estudio SIMETAP","doi":"10.1016/j.arteri.2022.03.006","DOIUrl":"10.1016/j.arteri.2022.03.006","url":null,"abstract":"<div><h3>Introduction</h3><p>Excess weight is a major health problem. Aims of this study were to determine the prevalence rates of overweight and obesity, and to compare their associations with cardiometabolic and renal risk factors between obese and non-obese populations, and between overweight and non-overweight populations.</p></div><div><h3>Methods</h3><p>Cross-sectional observational study conducted in Primary Care. Population-based random sample: 6,588 study subjects between 18 and 102 years of age (response rate: 66%). Crude and sex- and age-adjusted prevalence rates of overweight and obesity were calculated, and their associations with cardiometabolic and renal variables were assessed by bivariate and multivariate analysis.</p></div><div><h3>Results</h3><p>The age- and sex-adjusted prevalence rates of overweight and obesity were 36.0% (42.1% in men; 33.1% in women) and 25.0% (26.2% in men; 24.5% in women), respectively. These prevalences increased with age, and were higher in men than in women. Fifty-two percent (95%<span>C</span>I: 50.0-53.9) of the overweight population and 62.3% (95%CI: 60.1-64.5) of the obese population had a high or very high cardiovascular risk. Abdominal obesity, physical inactivity, prediabetes, hypertension, hypertriglyceridemia, and low HDL-C were independently associated with both entities. Furthermore, diabetes was independently associated with overweight and hypercholesterolemia with obesity.</p></div><div><h3>Conclusions</h3><p>The prevalence of overweight and obesity was 61.0% (68.4% in men and 59.0% in women). More than half of the overweight population and nearly two-thirds of the obese population had a high cardiovascular risk. Hyperglycemia, physical inactivity, hypertension, hypercholesterolemia, low HDL-C, and hypertriglyceridemia were independently associated with overweight and obesity.</p></div>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"34 6","pages":"Pages 291-302"},"PeriodicalIF":1.6,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54194802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
¿Por qué los osos pardos están protegidos contra la aterosclerosis a pesar de que sus niveles de colesterol plasmático doblan al de los humanos? 为什么棕熊的血浆胆固醇水平是人类的两倍,却能预防动脉粥样硬化?
IF 1.6 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2022-11-01 DOI: 10.1016/j.arteri.2022.09.001
Eva Hurt-Camejo , Matteo Pedrelli

Plasma cholesterol and triglyceride levels are twice as high in hibernating brown bears (Ursus arctos) than in healthy humans. Yet, bears display no sign of atherosclerosis development. To explore this apparent paradox, we analyzed lipoproteins from same ten individual bears plasma collected during winter (hibernation; February) and summer (active; June) in the same year. Plasma from fourteen healthy humans were analyzed as comparator. We used standard methods for lipoprotein isolation, composition and functional investigation. The results shows that in brown bears the absence of atherosclerosis despite elevated cholesterol is likely associated with two main athero-protective properties of circulating lipoproteins. First, a significant ten times lower affinity of low-density-lipoprotein (LDL) particles for arterial proteoglycans and secondly, an elevated plasma cholesterol efflux capacity. What does the brown bear data tell us? That elevated total cholesterol and ApoB-containing lipoproteins not always associates with atherosclerosis disease. We need to look also at the lipoprotein biochemical features and functionality as they are relevant for arterial pathophysiology. What is the translatability into human of these results? We humans need to control our total and LDL-cholesterol levels. We are not brown bears!

冬眠中的棕熊的血浆胆固醇和甘油三酯水平是健康人的两倍。然而,熊没有表现出动脉粥样硬化发展的迹象。为了探究这一明显的悖论,我们分析了在冬季(冬眠;2月)和夏季(活跃;同年六月)。分析了14名健康人的血浆作为比较物。采用标准方法对脂蛋白进行分离、组成和功能研究。结果表明,在棕熊中,尽管胆固醇升高,但没有动脉粥样硬化,这可能与循环脂蛋白的两个主要的动脉粥样硬化保护特性有关。首先,低密度脂蛋白(LDL)颗粒对动脉蛋白聚糖的亲和力显著降低了10倍;其次,血浆胆固醇外排能力升高。棕熊的数据告诉我们什么?总胆固醇和载脂蛋白含量升高并不总是与动脉粥样硬化疾病相关。我们还需要研究脂蛋白的生化特征和功能,因为它们与动脉病理生理有关。这些结果的可翻译性是什么?我们人类需要控制总胆固醇和低密度脂蛋白胆固醇水平。我们不是棕熊!
{"title":"¿Por qué los osos pardos están protegidos contra la aterosclerosis a pesar de que sus niveles de colesterol plasmático doblan al de los humanos?","authors":"Eva Hurt-Camejo ,&nbsp;Matteo Pedrelli","doi":"10.1016/j.arteri.2022.09.001","DOIUrl":"10.1016/j.arteri.2022.09.001","url":null,"abstract":"<div><p>Plasma cholesterol and triglyceride levels are twice as high in hibernating brown bears (<em>Ursus arctos</em>) than in healthy humans<em>.</em> Yet, bears display no sign of atherosclerosis development. To explore this apparent paradox, we analyzed lipoproteins from same ten individual bears plasma collected during winter (hibernation; February) and summer (active; June) in the same year. Plasma from fourteen healthy humans were analyzed as comparator. We used standard methods for lipoprotein isolation, composition and functional investigation. The results shows that in brown bears the absence of atherosclerosis despite elevated cholesterol is likely associated with two main athero-protective properties of circulating lipoproteins. First, a significant ten times lower affinity of low-density-lipoprotein (LDL) particles for arterial proteoglycans and secondly, an elevated plasma cholesterol efflux capacity. What does the brown bear data tell us? That elevated total cholesterol and ApoB-containing lipoproteins not always associates with atherosclerosis disease. We need to look also at the lipoprotein biochemical features and functionality as they are relevant for arterial pathophysiology. What is the translatability into human of these results? We humans need to control our total and LDL-cholesterol levels. We are not brown bears!</p></div>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"34 6","pages":"Pages 322-325"},"PeriodicalIF":1.6,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0214916822001140/pdfft?md5=89c6bc1b107e8d38ba4434c83c96cb16&pid=1-s2.0-S0214916822001140-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40669427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Clinica e Investigacion en Arteriosclerosis
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1